HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
SNDX
Syndax Pharmaceuticals Inc
Healthcare Biotechnology · Massachusetts, USA · Reports in usd
Market Cap: $1.83B
Market Cap
$1.83B
Enterprise Val
$1.76B
P/E Ratio
-6.39
P/B Ratio
28.24
Trailing PEG (1Y)
0.22
As Of
Apr 26, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value$64.6M
Gross Margin96.06%
Profit Margin96.06%
Return on Equity-206.62%
Return on Assets-49.25%
Current Ratio4.40
Debt/Equity5.34
LT Debt/Equity5.34
Revenue Per Share0.79

Income Statement

Dec 31, 2025
Revenue$68.7M
Cost of Revenue$2.7M
Gross Profit$66.0M
R&D$78.6M
SG&A$49.9M
Operating Expenses$128.6M
Operating Income-$62.5M
Interest Expense$9.6M
Tax Expense$0.00
Net Income-$68.0M
EPS (Basic)$-0.78
EPS (Diluted)$-0.78
EBIT-$58.4M
EBITDA-$58.0M
Consolidated Income-$68.0M
Non-Controlling Interests$0.00

Balance Sheet

Dec 31, 2025
Cash & Equivalents$135.0M
Accounts Receivable$68.1M
Inventory$32.8M
Current Assets$528.1M
LT Investments$0.00
Property, Plant & Equipment$1.5M
Intangibles$0.00
Non-Current Assets$1.6M
Total Assets$529.7M
Accounts Payable$16.6M
Current Debt$472.0K
Current Liabilities$120.1M
LT Debt$345.0M
Non-Current Liabilities$345.0M
Total Liabilities$465.1M
Total Debt$345.4M
Retained Earnings-$1.51B
Shareholder Equity$64.6M
Shares Outstanding86,914,838

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow-$69.5M
Investing Cash Flow$81.6M
Financing Cash Flow$5.9M
CapEx-$56.0K
Free Cash Flow-$69.5M
Depreciation & Amort.$398.0K
Stock-Based Comp$11.3M
Acquisitions / Disposals$0.00
Investment Activity$81.6M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$5.9M
Dividends Paid$0.00
Net Change in Cash$18.0M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h